greeksoup/ stock research
Stock research / United States / NVCR / Filings

NovoCure Ltd. SEC filings

NovoCure filed 26 documents with the SEC in the last twelve months, the latest report being the 10-Q of 23 July 2026. The latest filing, on 1 October 2026, was an 8-K: regulation fd disclosure.

Filings in twelve months2618 of them 8-K news
Latest report10-Qfiled 23 Jul 2026
Latest filing8-K1 Oct 2026
Last results, two-day move+13.4%results filed 23 Jul 2026
New to this? How to read this page
  1. Companies file with the SEC when something happens. 10-Q and 10-K are the quarterly and annual reports; 8-K is news that cannot wait for the next report.
  2. An 8-K says which items it covers, such as results, a change at the top or a big contract. A foreign company files a 6-K instead.
  3. The results release is usually an 8-K filed the day results come out, before the 10-Q or 10-K.
  4. Every filing links to the original on EDGAR, the SEC's own site.

Twelve months of filings

by kind

Most of the filings were other company news (13). Results came out 5 times.

Each mark is one filing on the day it was filed, in rows by kind. Hover or tap a mark for the form and what it was about.

The share price around each results release

close before to close after

Over the last 5 releases the share price moved 14.3% on average in the two days around results, the most on 30 Apr 2026 (+39.3%).

12 Jan 2026-4.9%$14.35 to $13.65
26 Feb 2026-8.8%$14.99 to $13.67
30 Apr 2026+39.3%$11.93 to $16.62
23 Jul 2026+13.4%$15.57 to $17.65
Daily closeResults filed

Each ring marks a results filing. The move runs from the last close before the filing to the first close after it, so it covers results released before the open or after the close. Hover the line for any day's close.

What the company told investors on 8-K

18 filings

NovoCure's 18 news filings (8-K) were mostly about regulation FD disclosure (8) and officer or director change (5).

  • Regulation FD disclosureMaterial shared with investors, often slides or a presentation
    8 · latest 1 Oct 2026
  • Officer or director changeSomeone joined, left or changed role at the top
    5 · latest 9 Sep 2026
  • Results of operationsThe quarterly results release
    5 · latest 23 Jul 2026
  • Other eventsNews the company chose to file
    1 · latest 1 Sep 2026
  • Shareholder voteResults of a vote at a shareholder meeting
    1 · latest 5 Jun 2026

Each line is one kind of news, with what it means in plain words. Each square is one filing; a filing can carry more than one kind, so the squares can add up to more than the filings. The date opens the latest one on EDGAR.

How it compares

every company on the site

    The bar ranks every company on the site from the lowest on the left to the highest on the right, in three equal thirds; the small figures under it are the values where each third starts, and the black tick is the middle company. The orange dot is this company; the grey ticks are the other companies in its industry (hover or tap for names). A hatched block is companies tied at none.

    Every filing as a table

    In the last twelve months NovoCure Ltd. filed 26 documents with the SEC of the kinds listed here: 18 current reports (8-K), about 8 regulation FD disclosure; 5 officer or director change; 5 results of operations; 1 other events; 1 shareholder vote; 3 quarterly reports (10-Q), 2 additional proxy materials (DEFA14A), 1 proxy statement (DEF 14A), 1 employee share plan registration (S-8), 1 annual report (10-K). The latest, filed 1 October 2026: 8-K, regulation FD disclosure. The 10-K, the 10-Qs and the proxy statement themselves, each with a link to open it, are on the documents page.

    FiledFormWhat it was aboutPeriod or event dateFiling
    1 October 20268-KRegulation FD disclosure1 October 2026EDGAR
    9 September 20268-KOfficer or director change2 September 2026EDGAR
    1 September 20268-KOther events1 September 2026EDGAR
    23 July 20268-KResults of operations23 July 2026EDGAR
    23 July 202610-Qquarterly report30 June 2026EDGAR
    30 June 20268-KRegulation FD disclosure30 June 2026EDGAR
    18 June 20268-KRegulation FD disclosure18 June 2026EDGAR
    5 June 20268-KOfficer or director change, Shareholder vote3 June 2026EDGAR
    21 May 2026DEFA14Aadditional proxy materialEDGAR
    30 April 20268-KResults of operations30 April 2026EDGAR
    30 April 202610-Qquarterly report31 March 2026EDGAR
    24 April 20268-K/AOfficer or director change24 November 2025EDGAR
    20 April 2026DEFA14Aadditional proxy materialEDGAR
    20 April 2026DEF 14Aproxy statement3 June 2026EDGAR
    9 April 20268-KOfficer or director change8 April 2026EDGAR
    26 March 20268-KRegulation FD disclosure26 March 2026EDGAR
    26 February 2026S-8employee share plan registrationEDGAR
    26 February 20268-KResults of operations26 February 2026EDGAR
    26 February 202610-Kannual report31 December 2025EDGAR
    24 February 20268-KRegulation FD disclosure24 February 2026EDGAR
    11 February 20268-KRegulation FD disclosure11 February 2026EDGAR
    5 February 20268-KRegulation FD disclosure30 January 2026EDGAR
    12 January 20268-KResults of operations12 January 2026EDGAR
    1 December 20258-KOfficer or director change, Regulation FD disclosure24 November 2025EDGAR
    30 October 20258-KResults of operations30 October 2025EDGAR
    30 October 202510-Qquarterly report30 September 2025EDGAR
    An 8-K is what a company files within four business days of a material event; the SEC numbers the events, and the words here are the SEC's own headings, shortened.
    Read moreForm 4, Form 144, 13F and Schedule 13D and 13G have their own pages. Prospectus supplements and correspondence are not listed.